ARTCLINE Appoints Dirk Hessel as Managing Director and Prepares Market Entry for Innovative Septic Shock Treatment

ARTCLINE has announced the appointment of Dirk Hessel as Managing Director. Hessel brings extensive experience in sales and marketing of medical devices and biopharmaceutical products. He will co-lead the company’s strategic growth and market entry for the ARTICE® therapy.

ARTICE® is an innovative therapy using immune cells from healthy donors to treat septic shock patients. This treatment aims to strengthen patients' immune systems. Clinical benefits have been demonstrated in two studies, including the ongoing ReActIF-ICE study in Germany, enrolling 142 patients.

Sepsis affects 48 million people annually and accounts for 20% of global deaths. Despite advancements, the mortality rate remains high. Patients often die from secondary infections post initial survival. Hessel’s appointment is seen as pivotal for ARTCLINE's market positioning and commercial success.

Dirk Hessel has held leadership positions in the biotechnology and pharmaceutical industries, including CEO roles in companies focused on cancer detection and advanced therapy medicinal products. His expertise is expected to drive ARTCLINE’s innovative septic shock treatment forward.